

Special Issue

Recent Advances in Malaria Vaccine Development—2nd Edition

Message from the Guest Editors

Infections caused by malaria parasites constitute a major burden on human health in affected regions globally. As one of the deadliest parasitic diseases, malaria continues to cause significant morbidity and mortality, with an estimated 263 million clinical cases and 597,000 deaths reported in 2023*. Increasing resistance to anti-malarial drugs continues to be a major concern in the fight against the disease.

While *Plasmodium falciparum* causes the majority of malaria-related mortality, safe and efficacious vaccines for both *P. falciparum* and *P. vivax* are needed as cost-effective tools for the prevention and elimination of malaria globally. Importantly, in addition to the only two recently recommended vaccines for the prevention of falciparum malaria in children living in endemic areas (RTS, S/AS01B and R21/Matrix-M), multiple vaccines are required against malaria to provide high efficacy and meet the malaria vaccine supply capacity. This Special Issue of *Vaccines* aims to showcase new developments in both falciparum and vivax malaria vaccines. We look forward to your contributions.

Guest Editors

Dr. Ahmad R. Shakri

Division of Infectious Disease and International Medicine, Department of Internal Medicine, University of South Florida, 3720 Spectrum Blvd, Tampa, FL 33612, USA

Dr. Dipak Raj

Division of Infectious Disease and International Medicine, Department of Internal Medicine, University of South Florida, 3720 Spectrum Blvd, Tampa, FL 33612, USA

Deadline for manuscript submissions

31 December 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/250755

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).